Estrella Immunopharma, Inc. (ESLA)
NASDAQ: ESLA · Real-Time Price · USD
1.580
-0.100 (-5.95%)
At close: Apr 28, 2026, 4:00 PM EDT
1.530
-0.050 (-3.16%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Estrella Immunopharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Estrella Immunopharma stock has a target of 8.00, which predicts an increase of 406.33% from the current stock price of 1.58.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 9, 2026.
Analyst Ratings
According to 1 stock analyst, the rating for Estrella Immunopharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $8 | Strong Buy | Maintains | $8 | +406.33% | Feb 9, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $16 → $8 | Strong Buy | Maintains | $16 → $8 | +406.33% | Jan 28, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $16 | Strong Buy | Maintains | $16 | +912.66% | Nov 3, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $16 | Strong Buy | Maintains | $16 | +912.66% | Aug 12, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $16 | Strong Buy | Maintains | $16 | +912.66% | Jun 3, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.40
from -0.35
EPS Next Year
-0.33
from -0.40
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.41 | -0.34 | ||||||
| Avg | -0.40 | -0.33 | ||||||
| Low | -0.38 | -0.31 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.